Lesson plan

Prodipine

Prodipine ( ; developmental code name BY-101) is an experimental antiparkinsonian agent of the 4,4-diphenylpiperidine series related to budipine which was never marketed. It was the predecessor of budipine and was similarly found to be effective in the treatment of Parkinson's disease. However, prodipine produced side effects including gastrointestinal adverse effects, nausea and vomiting, and hypotension. Due to the nausea and vomiting with the oral form, it could only be tolerated with intravenous administration. As a result, budipine, which had fewer side effects, was developed instead.

Back to article

Article summary

Prodipine ( ; developmental code name BY-101) is an experimental antiparkinsonian agent of the 4,4-diphenylpiperidine series related to budipine which was never marketed. It was the predecessor of budipine and was similarly found to be effective in the treatment of Parkinson's disease. However, prodipine produced side effects including gastrointestinal adverse effects, nausea and vomiting, and hypotension. Due to the nausea and vomiting with the oral form, it could only be tolerated with intravenous administration. As a result, budipine, which had fewer side effects, was developed instead.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.